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Abstract
Modern science takes at face value the fact that exercise is beneficial for man’s health. In recent years, medical health profession-
als have begun to harness exercise as a treatment for a broader range of maladies . Since various studies found increased exercise 
to correlate with higher levels of endorphins, most believed that the endorphins were directly responsible for what the vernacular 
dubbed “Runner’s High.” Scientists have sought to either augment or wholly disprove the endorphin hypothesis with further 
studies. Major Depressive Disorder, or MDD, is an affective condition affecting a significant portion of the general population. 
Aerobic exercise is increasingly being revealed to be an encouraging treatment for all types of depression and anxiety . The HPA 
Axis allows one to comfortably exercise without experiencing the extremely stressful symptoms that characterize psychological 
stress, such as depression, anxiety, fear, etc. Runners’ High is the “…happiness, elation…inner harmony, boundless energy, and…
reduction in pain sensation” that ensues following prolonged aerobic activity. Endorphins are the body’s naturally occurring opiates. 
The Neurogenesis Hypothesis states that “a decrease in the synthesis of new neurons in the adult hippocampus might be linked 
to major depressive disorder .” Further research implicates BDNF (Brain-Derived Neurotrophin Factor) in exercise-induced neuro-
genesis . The thought was that beta endorphins are what stimulate increased neurogenesis, in turn causing a decrease in MDD . 
β-endorphins are large molecules that are too bulky to pass through the BBB and therefore cannot be the cause any changes to 
occur within the brain . Researchers and scientists have thus turned their attention to endogenous endocannabinoids as the true 
source of analgesia, sedation, anxiolysis and reduced depression found in endurance exercisers . Chief ligand anandamide (AEA) 
engenders elevated levels of BDNF (Brain Derived Neurotrophic Factor) during exercise and return-to-baseline levels post-exer-
cise . Endocannabinoids modulate nociception by affecting the Periaqueductal Gray system (PAG) . Endogenous cannabinoids and 
exogenous cannabinoids (marijuana) act in similar fashions, leading to the addictive qualities of exercise . Compelling evidence has 
ascertained that endogenous endocannabinoids are the underlying cause of the many positive effects of aerobic activity .
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Introduction
Modern science takes as face value the fact that exercise is 
beneficial for man’s health. Hippocrates was known to say, 
“Even when all is known, the care of a man is not yet complete, 
because eating alone will not keep a man well; he must also 
take exercise...” While to a contemporary society this concept 
seems rather primitive and simplistic, it is a truth that forms 
the basis of modern health sciences. However, it has only been 
in recent years that medical health professionals have begun to 
harness exercise as a treatment for a broader range of maladies. 
Exercise is widely known to help keep one’s weight down, tone 
muscles and enhance physical fitness. Scientists are perpetually 
expanding their knowledge of exercise and what kind of effects 
it has on the brain and the body’s systems. An understanding 
of the neuronal activity, neurotransmitter actions and chemical 
releases that are the responses to varying degrees of exercise 
can be applied to treat disease and improve lives. One such 
application is exercise as a treatment for Major Depressive 
Disorder (MDD). MDD had previously been treated solely with 
antidepressants, but more recently is being dealt with using a 
combination of medication and exercise. Various case studies 
have undertaken to prove the relationship between exercise 
and positive changes in the MDD brain. Once the neuronal and 
chemical effects of exercise were established, it naturally led 
to the conclusion that depressive symptoms lessened due to a 
proliferation of certain positive hormones that were released 
into the brain in response to exercise. With further investiga-
tions, the popular conclusion was that the feel-good high asso-
ciated with exercise is caused by endorphins, opioid hormones 
that appear to increase in response to exercise. Since various 
studies found increased exercise to correlate with higher levels 
of endorphins, most believed that the endorphins were directly 
responsible for what the vernacular dubbed “Runner’s High.” 
Since then, scientists have sought to either augment or wholly 
disprove the endorphin hypothesis with further studies.
Methods
The search engines used include ProQuest, EbscoHost, and 
GoogleScholar. Tributary information was also obtained using 
Wikipedia, the New York Times and WebMD.
Discussion
Major Depressive Disorder, or MDD, is an affective condition 
affecting a significant portion of the general population. In 
America today, about 5% of all people will eventually be diag-
nosed with MDD. Quality of life with MDD is radically impaired, 
and basic life functions such as eating, sleeping and maintaining 
personal hygiene can be affected. It has been found that rough-
ly 10% of people diagnosed with MDD will probably commit 
suicide. This is all due to the overwhelming, pervasive feel-
ings of severe depression that characterize Major Depressive 
Disorder. Deficits in executive function are also consequences 
of MDD. Patients tested with a Stroop Task, Go/No Go Task, 
Task-Switching Paradigm and Flanker Tasks all scored low in 
reaction times, indicating deficits in executive function ability 
(Ernst, et al. 2006). Previously, MDD had been treated solely 
with antidepressant medications such as SSRIs (selective sero-
tonin reuptake inhibitors). The anti-depressant medication field 
is an ever-growing industry, despite limited success and many 
unwarranted side effects. For examples, anti-depressants stop 
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working after a while, since the body and brain become accus-
tomed to the drug and gain a tolerance for it. In such a case, 
the dose would have to continuously be raised in order to have 
any effect. Furthermore, if one abruptly stops taking the dosage 
of medication, withdrawal symptoms such as “dizziness, loss of 
coordination, fatigue, tingling, burning, blurred vision, insomnia, 
and vivid dreams” may incur.  Additionally, the patient may expe-
rience “nausea or diarrhea, flu-like symptoms, irritability, anxiety, 
and crying spells.” This tendency is called the “Discontinuation 
syndrome” and is obviously best to be avoided. Other nega-
tive side effects might include insomnia, diarrhea and stomach 
aches, headaches, joint and muscle pain, reduced blood clotting 
capacity due to lowered concentration of serotonin in plate-
lets and possible increased tendency towards violence and/or 
self-destructive behaviors. A Black Box warning was even issued 
in 2004 by the FDA against SSRIs, warning of the possible risk of 
“suicidal thoughts, hostility, and agitation in children, teens and 
young adults” (Harvard, 2019).
Between 30-35% of patients on medication do not even re-
spond to the antidepressant treatment at all. The unpleasant 
side effects considerably compromise the patients’ quality of 
life in many areas and make the medications undesirable as a 
primary treatment for depression. Furthermore, there is a high 
relapse rate found in patients treated with antidepressants, lead-
ing to a need for alternative and/or supplementary treatments 
(Blumenthal, et al. 1999).
Aerobic exercise is increasingly being revealed to be an en-
couraging treatment for all types of depression and anxiety 
(Heijnen, et al. 2016). A study was performed testing MDD 
symptoms in response to exercise. Participants were accepted 
for the study if they displayed depressive criteria as expressed 
in the DSM-IV and other symptoms such as “sleep disturbance, 
weight loss…psychomotor retardation or agitation, feelings of 
worthlessness or excessive guilt, impaired cognition…and re-
current thoughts of death.” They also had to receive a score of 
at leave 13 on the HAM-D test. The HAM-D is a clinical rating 
scale used to measure levels of depression. Scores of thirteen 
to eighteen is mildly depressed, above 18 is severely depressed. 
Each of the subjects of the study were assigned to one of three 
groups – exercise treatment, medication treatment, and a com-
bination of exercise and medication treatment. The assignment 
of groups was a randomized procedure to ensure that equally 
depressed participants were assigned across the groups. The 
exercise group met three times a week for 16 weeks, engaging 
in personalized exercise protocol according to their individual 
heart rate capability. The classes were overseen by a “trained 
exercise physiologist.” The medication group was administered 
the SSRI sertraline, specifically used due to its “documented 
efficacy and favorable side effect profile.” Dosages were admin-
istered by the staff psychiatrist at intermittent weeks. The com-
bination group concurrently received the same medication and 
exercise regimens described above. Results were generally pos-
itive. Firstly, patients who engaged in exercise showed improve-
ments in aerobic capability, with an 11% increase in the exercise 
group and a 9% increase in the combination group. Secondly, 
depressive symptoms improved equally across all three groups. 
Improvements on the HAM-D scores did not differ across 
groups, and neither did the scores based on DSM-IV depres-
sion criteria. “…The percentage of patients who were no lon-
ger classified as clinically depressed at the end of the 4-month 
treatment period did not differ across treatment groups.” The 
only difference found that they patients benefited more rapidly 
in the combination group than did the patients in the exercise 
or medication groups alone. This study demonstrated that ex-
ercise treatment as an intervention for depression is equally as 
effective as medication treatment (Blumenthal, et al. 1999).
Numerous other studies, all of which sought to prove the efficacy 
of exercise have tested people who suffer from depression across 
the spectrum. One set of studies has shown that participants, rang-
ing from young to elderly, who engage in daily exercise regimens 
are far less likely to develop MDD. Subsequent investigation further 
demonstrated that daily exercise improves depressive symptoms, 
even in people who have not been diagnosed with MDD. Exercise 
studies performed with healthy adults with no depressive symp-
toms also found positive results. These adults reported improved 
cognitive function, elevated mood and a general sense of well-being. 
One study tested how well exercise treated “moderate-to-severe” 
depression, concluding that the depression was highly improved. 
Another treated MDD patients with a combination of antidepres-
sant medication and exercise regimens. A control group received 
medication and “health education” lessons. The medication/exer-
cise group responded significantly better than the control group. 
Yet another tested a group of adults suffering from MDD, exercis-
ing with varying intensities of exercise. They found here that the 
most intense exercise group improved the most. A significant edge 
that exercise has over medication is that the effects of exercise may 
extend past the actual regimen, with the positive feelings enduring 
(in one study) up to almost two years past the experiment (Ernst, 
et al. 2006). This is in sharp contrast to antidepressant medication, 
of which the healing abilities curtail immediately with the end of 
dosage. This is why people on medication require concurrent ther-
apy so that they can manage their life even after their medication 
dosage is over. On the other hand, exercise is found to be even 
superior to therapy itself in many instances, with various “young 
and middle-aged adults” positing that aerobic exercise helped their 
depressive symptoms more than therapies like psychotherapy, CBT 
and occupational therapy (Blumenthal, et al. 1999). Aerobic exercise 
performed by patients with depression and anxiety may improve 
cognitive function. (Heijnen, et al. 2016) Patients who scored poorly 
on various task functions, such as Stroop and Flanker Tasks, scored 
significantly higher following 30 minutes of aerobic exercise (Ernst, 
et al. 2006). All of these studies have consistently found lower MDD 
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and anxiety levels in response to exercise training, in addition to 
higher psychosocial functioning, increased positive affect and ele-
vated mood (Blumenthal, et al. 1999).
The obvious question that troubles scientists and mental 
health specialists is why exercise has such a potent effect on the 
human psyche. While the physical action of aerobic exercise is 
known to cause weight loss and increased fitness due to burning 
of calories and fat and muscle toning, the reason behind the 
mental effects are not as simple to extrapolate. Exploring the 
neuroendocrine response that takes place in response to aero-
bic exercise may help to ascertain the underlying cause.
Exercise that activates the heart rate from its resting point 
and raises the maximum capacity of oxygen intake (VO2max) at 
least 60% can be classified as a physical stressor. In response to 
such a stressor, the hypothalamus secretes “corticotrophin-re-
leasing hormone, which travels…to the anterior pituitary to 
induce adrenocorticotropic hormone (ACTH) release” into the 
general circulation. Arrival of this hormone at the adrenal cor-
tex stimulates cortisol release into the bloodstream. Cortisol 
acts as an inhibitor and, through the use of medial prefrontal 
cortex (mPFC) receptors, inhibits “overexcitability of the amyg-
dala” that naturally occurs when a stressor arrives in the blood-
stream (Heijnen, et al. 2016). This stress response is known as 
the Hypothalamic-Pituitary-Adrenal (HPA) Axis, so named for 
the journey of hormones from the hypothalamus, through the 
anterior pituitary and into the adrenal cortex, causing relax-
ation from the body’s increased stress levels (Blumenthal, et al. 
1999). The elevated levels of cortisol can last up to 2 hours after 
the actual exercise action, and the amount of cortisol released 
is proportional to the amount of exercise. Equally important 
in the stress response is the inactivation of cortisol back into 
cortisone. This homeostatic cycle ensures that frequent exer-
cisers do not suffer from extreme cortisol levels that can lead 
to “hypertension, hyperglycemia, major depressive episode and 
anorexia nervosa” (Heijnen, et al. 2016). Thus, ACTH is a regula-
tory mechanism that acts as the body’s natural stress response. 
This allows one to comfortably exercise without experiencing 
the extremely stressful symptoms that characterize psycholog-
ical stress, such as depression, anxiety, fear, etc. (Angelopoulos, 
2001). However, while this neuroendocrine response accounts 
for the control of increased psychological stressors while exer-
cising, it could hardly account for the flood of “euphoria, anxi-
olysis (reduction of anxiety), sedation, and analgesia (relief from 
physical pain)” that characterize what we call Runner’s High 
(Reynolds, 2015).
Runner’s high is the reason that America has its plethora of 
addicted runners clocking miles in their sneakers every day. 
Every athlete can describe the “…happiness, elation…inner har-
mony, boundless energy, and…reduction in pain sensation” that 
ensues following prolonged aerobic activity (Dietrich, 2004). 
This so-described high is experienced frequently by endurance 
athletes, but really by anyone who exercises profusely for an 
extended amount of time. Scientists have struggled for decades 
with the reason behind runner’s high and many hypotheses have 
been debuted and disproven over time. For years the Endorphin 
Hypothesis was the most popular by scientists and the overall 
population, gaining strength through hearsay and seemingly im-
penetrable evidence.
Endorphins are the body’s naturally occurring opiates. When 
a person exercises, these chemicals are released in the brain, 
seeming to improve the athlete’s mood and promote endurance. 
While exercise is known to be a healthful practice to engage in 
for one’s physical health, it can cause degrees of discomfort or 
even pain. Therefore, it would make sense that in response to 
exercise, endogenous opiates with antinociceptive properties 
similar to morphine would be released (Reynolds, 2015). Any 
kind of intense endurance exercise can induce endorphin re-
lease, and it seems that the greater the exercise, more mood-al-
tering endorphins are proportionately released (Kolata, 2008). 
Endorphins are “cleaved from the preprohormone pro-opiome-
lanocortin (POMC)…a protein found in the pituitary gland and 
the brain” (Ernst, et al. 2006). The C-terminus of the POMC 
protein in turn gives rise to hormones such as opiate peptides. 
In one experiment, researchers used PET (positron emission 
tomography) scans to compare endorphin levels in the brains 
of athletes. Ten athletes did a two-hour run and were tested 
for opiate levels before and after the run. Additionally, the run-
ners took a psychological test pre and post-run, intended to 
measure their moods before, and in response to, the flood of 
endorphins. The researchers did find increased levels of endor-
phins attaching themselves to the limbic and prefrontal areas of 
the brain, zones typically associated with emotion. The athletes 
also reported higher mood and euphoria in a seemingly direct 
relation to higher endorphin levels in the brain (Kolata, 2008, 
Heijnen, et al. 2016). Technically, all this study proved was that 
there is indeed a flood of endorphins in the brain in response to 
exercise. While there seems to also be a correlation between 
the elevated opiate levels and mood, the proof was not – yet 
– impenetrable.
A study performed at the Iranian Academic Center for 
Education, Culture and Research (ACECER) attempted to as-
certain how endorphin levels are affected due to exercise. The 
researchers included subjects with fibromyalgia (FM) as well as 
healthy patients. The study was based on the assumption that ex-
ercise increases release of endogenous β-endorphins, and that 
β-endorphins lessen pain perception. Exercise has previously 
been used as a treatment for diseases such as FM, with a strong 
role in nociception and elevated pain threshold. Specifically in 
FM cases, however, the “analgesic effect” or lessening of pain 
perception seemed significantly dulled. According to the results 
of the study, this would seem to be due to the fact that FM pa-
tients produce less β-endorphins as they exercise and therefore 
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are less capable of blocking pain. All of the subjects first rested 
in a supine position in order to attain their basal heart rate, a 
range of 60 to 100 beats per minute. Blood from the anti-cubital 
vein was drawn at baseline and at the end of the exercise test 
in order to compare β-endorphins levels. The exercise test was 
a treadmill routine that continued as long as the subject was 
able, until the onset of “fatigue, pain, or physical exhaustion”. 
Every three minutes the incline of the treadmill as well as the 
speed increased according to specific intervals. As soon as 70% 
of the patients HRMax (maximum heart rate) was achieved, the 
subject was told to continue for 15 more minutes only, and 
their level of exercise intensity was recorded. The post exercise 
blood was drawn directly afterwards, when the heart rate was 
still at its maximum. The results were rather interesting. The 
mean exercise times for the FM and healthy groups revealed 
that it took a much shorter time for the FM subjects to achieve 
HRMax than the healthy group. The majority of subjects who 
were able to reach their HRMax at later stages of exercise were 
from the healthy group. Ninety three percent of the healthy 
group, as opposed to the mere 30% of FM subjects, reached 
HRMax during stage four of exercise. This indicated that FM 
patients were unable to exercise to the same extent that the 
healthy participants were. While the blood samples indicated 
that both groups had amounts of β-endorphins, the FM subjects 
has significantly lower levels in both their baseline blood and 
in the post-exercise blood. This means that while both groups 
experienced a rise in β-endorphins due to the exercise, the FM 
patients were unable to produce the same influx of β-endor-
phins as the healthy group. These blunted levels of β-endorphins 
may explain why FM patients are more immune to the analgesic 
effects of exercise that usually take over post-exercise. Usually, 
aerobic exercise stimulates elevated β-endorphins levels which 
in turn seem to stimulate decreased nociception, elevated 
mood and psychological stability. However, due to “failure of 
normal elevation of [endogenous] β-endorphins,” FM patients 
seem less able to produce the same analgesic effects. Therefore, 
they might be more prone to develop chronic allodynia (pain 
from a non-painful stimulation of the skin) and heightened noci-
ception with the absence of normal β-endorphins levels (Bidari, 
et al. 2016).
Scientists have explored how endorphin levels rise in re-
sponse to exercise. A study sought to verify the elevated levels 
of endorphins, with and without naloxone (opiate antagonist). 
It has already been proven than exercise with an intensity of 
75% of VO2max and 80% of HR (heart rate) causes an elevated 
release of beta endorphins into circulation. However, this study 
examined whether longer lengths of activity cause even further 
increased endorphin levels, and how long one must exercise to 
stimulate endorphin release. The study included “nine healthy, 
fit males.” In this double-blind experiment, some subjects were 
injected with naloxone, and some with a mere placebo. They 
all took a graded exercise test (GXT) to assess their physical 
capabilities and then performed exercise on treadmills, running 
until they were too exhausted to go on. Phlebotomy techniques 
were used to draw blood and measure beta endorphin levels. 
Levels of VO2max, HR (heart rate) and hematocrit (ratio of 
RBC volume in blood) were measured during 10 min, 20 min 
and 30 min intervals for both trials. No changes in Hct levels 
were found between trials.
β-endorphin concentration across the trials were recorded 
and trials showed significant differences. Before exercise, β-en-
dorphins levels were at roughly 40 ml; across 10, 20 and 30-min-
ute intervals, influxes of 80 to 90 ml of β-endorphins were re-
corded. Of note is that after the initial rise in β-endorphins, the 
volumes leveled off and stopped rising across time during exer-
cise - it stayed constant.  β-endorphin levels were significantly 
higher under naloxone administration. To summarize the results 
of the study, a significantly large increase in β-endorphin were 
found during and throughout exercise as compared to resting 
levels. They also found that the men injected with Naloxone ex-
perienced even higher levels of β-endorphins. Additionally, tests 
with low to moderate levels of exercise showed no changes 
at all in β-endorphin levels. Therefore, this suggests that it is 
only intense aerobic exercise that induces significant increases 
in β-endorphins. This elevation occurs rapidly from the onset 
of exercise and remains level through the duration. This test 
found much higher β-endorphin levels in the naloxone-injected 
participants as compared to the placebo participants. However, 
other experiments did not find much of a difference between 
naloxone test and placebo test. This is an obvious disparity that 
may be due to “differences in the exercise protocol, method of 
administration of the antagonist, and in the stereo-specificity of 
the antagonist used in the respective experimental protocols” 
(Angelopoulos, 2001).
Now the question stands, what is it that causes this dras-
tic β-endorphins rise during exercise? The researchers suggest 
that Naloxone attaches to the opioid receptor, blocking any 
other opiates and signaling the pituitary gland to release more 
β-endorphins. These β-endorphins do glucoregulation during 
exercise, “augmenting glucagon levels and attenuating insulin 
release.” Glucagon keeps blood glucose at high enough levels 
to allow the body to function normally (Glucagon, Diabetes.
Co). This is a positive feedback loop – more β-endorphin is re-
leased, it does more glucoregulation, and so more β-endorphin 
is released. This may be why endorphin levels were higher with 
Naloxone injections. 
ACTH also increases under stressful condition, just like β-en-
dorphins. ACTH is also secreted by the pituitary and regulates 
cortisol in the bloodstream. Just like the endorphins in this 
study, ACTH levels rise with an injection of Naloxone. Thus, it 
seems that both β-endorphins and ACTH are regulatory mech-
anisms, acting to ensure the body’s homeostasis despite outside 
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stressors. However, ACTH regulates the psychological stress 
response and endorphins normalize the physical response. 
This study demonstrated how and why β-endorphins levels 
were significantly elevated over the course of aerobic activity 
(Angelopoulos, 2001).
It is clear that aerobic exercise indeed causes an influx of 
β-endorphins to be released into blood circulation. The next step 
would be to secure as fact that it is indeed the flood of endorphin 
opiates that lowers depressive symptoms and induces a euphoric 
affect. The following study attempted to ascertain the possible 
link between aerobic exercise and the subjects’ emotional state. 
The study involved middle aged subjects engaging in physical ac-
tivity. First off, the subjects’ emotional states were evaluated using 
FaceReader. FaceReader is a facial analysis software that assesses 
emotional state based on 6 primary emotions - happy, sad, angry, 
disgusted, scared, and surprised. The subjects were also inter-
viewed personally to assess how they were feeling just then. After 
the facial analysis the researchers drew blood from the median 
cubital vein of each subject to have a baseline sample of blood 
plasma levels. The physical activity was measured using a veloer-
gometer load test. A veloergometer is similar to an elliptical exer-
cise bike, however it is equipped with specialized hardware capa-
ble of measuring physical prowess. This exercise regimen is called 
a load test, and it commenced for a half hour, with increasing 
load every three minutes.  After the load test, the pre-test proce-
dures – FaceReader, interview and phlebotomy – were repeated 
and analyzed. The pre and post blood measures were tested for 
plasma beta endorphin levels to see if there was an increase in 
endorphins in response to the exercise. If an increase was accom-
panied by a similar increase in mood, this would provide evidence 
that it is endorphins that cause the elevated mood associated 
with physical activity. The results showed an endorphin increase in 
only half of the subjects. However, in regard to positive affect, the 
data found a general increase across the subjects. A 20% increase 
in happiness was found and all except one showed a decrease in 
negative emotions. (One subject showed an increase in disgust 
due to unpleasant lab conditions) (Kundzina, et al. 2014). These 
findings definitively supported the hypothesis that extended aer-
obic exercise of at least 60% VO2 intensity is directly linked to 
increased positive affect and decreased depressive symptoms. It 
is of significance to note, however, that only half of the subjects 
showed a marked increase in circulating beta endorphin levels. 
Here we introduce a hypothesis that closely allies with the sub-
ject at hand. This is the Neurogenesis Hypothesis, which states 
that “a decrease in the synthesis of new neurons in the adult hip-
pocampus might be linked to major depressive disorder (MDD).” 
Anti-depressant medications such as SSRIs have been used for 
years as treatment for MDD. Anti-depressants act to stimulate 
synthesis of new neurons in the adult brain. Eventually, a link was 
drawn between the anti-depressants and neurogenesis, since the 
time it takes for medication to have an effect is the same span of 
time it takes for the newly synthesized neurons to gain function-
ality. Returning to our exercise hypothesis, an experiment with 
lab rats found a 2 to 3-fold increase in neurogenesis in rats who 
had “regular access to a running wheel when they are compared 
with control animals.” This discovery naturally led to the aware-
ness that exercise assuages depressive symptoms by inducing 
increased neurogenesis, the “growth of new neurons in the adult 
[mammalian] brain.” While it was once thought that neurogenesis 
is limited to the developmental stages of growth, it is now known 
that certain areas of the adult mammalian brain retain active pro-
genitor cells that are constantly synthesizing new neurons and glial 
cells. There are two major sites of adult neurogenesis, the dentate 
gyrus of the hippocampus and the subventricular zones adjacent 
to the lateral ventricles. Based on experiments performed with 
lab mice and rats, roughly 9,000 new neurons are synthesized 
daily in the dentate gyrus alone. Research indicates that these 
numbers are reflective of human neurogenesis as well (Ernst, et 
al. 2006).  One site of adult neurogenesis is the subventricular 
zone (SVZ) that is adjacent to the lateral ventricles of the brain. 
“Numerous proliferative precursor cells” line the walls of the 
ventricles that are composed of ependymal cells. The precursor 
cells are contained in this zone and eventually mature into new 
neurons and glial cells. The second site is the dentate gyrus (DG), 
located on the hippocampus in the brain. The hippocampus, a 
“bilateral limbic structure that plays a role in…learning and mem-
ory....” has two distinct areas – the Cornu Ammonis (CA) and the 
dentate gyrus. The CA has three subfields filled with pyramidal 
cells, multi polar neurons that act as primary excitation neurons 
in the brain. The dentate gyrus is connected to the CA and is 
“composed of small, round granule cells” that form a C shaped 
area. It is underneath these granule cells that active progenitor 
cells are housed and give rise to new neurons and glia, giving the 
area its name – the subgranular zone (SGZ) of the dentate gyrus. 
The two zones are closely adjacent to each other but develop 
differently. Active progenitor cells in the dentate gyrus give rise 
to daughter cells that migrate into the granule layer above. There, 
they develop and send out axons into the Cornu Ammonis region 
3 (CA3). Over the course of four to five weeks, these daughter 
cells mature and act like fully grown granule cells. The daughter 
cells in the subventricular zone give rise to daughter cells that 
migrate into the olfactory bulbs to act as local interneurons. Thus, 
there is adult neurogenesis occurring daily at a rapid rate in the 
healthy mammalian brain. The neurogenesis theory states that if 
this complex process should somehow be impaired and fewer 
neurons would be created, the result would be the expression 
of depressive symptoms. The introduction of anti-depressant 
medications would promote neurogenesis and get the brain back 
on track. The plot thickens with the discovery that exercise too, 
promotes neurogenesis in the hippocampus of the brain. This 
strongly links exercise as a reliable therapeutic intervention for 
treatment of MDD (Ernst, et al. 2006).
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Several research experiments have sought to augment the 
proof with concrete data. Firstly, MRI (magnetic resonance im-
aging) data have shown that hippocampal volume is severely 
compromised in the brains of depressed patients. This would 
give strength to the idea that it is reduced neurogenesis in the 
dentate gyrus that gives rise to depressive symptoms. Other 
studies showed that the corticosteroids released from the ad-
renal gland as part of the natural stress response (HPA Axis) 
negatively impact neurogenesis in the hippocampus, thus caus-
ing the “decreased hippocampal volume associated with MDD.” 
The stress response is thus amplified, sustaining a vicious cycle 
of continuous depression and stress response. It’s important to 
note that the decreased size of the hippocampus is not due to 
the degeneration of pre-existing neurons. Therefore, it would 
follow that fewer neurons are being created in the first place. 
Comparatively, researchers found increased hippocampal vol-
ume in direct relation to aerobic exercise. Lab rats that engaged 
in aerobic exercise consistently displayed large increases in hip-
pocampal volume due to subsequent supplementary neurogen-
esis. As compared to control mice and rats with no access to a 
running wheel, active mice displayed double the number of new 
neurons in the subgranular zone of the dentate gyrus of the 
hippocampus. Furthermore, it has been ascertained that treat-
ments for MDD, such as SSRIs (selective serotonin reuptake 
inhibitors) or electroconvulsive shock therapy, also cause an in-
crease in neurogenesis. This expresses a direct relationship be-
tween neurogenesis and lessening depressive symptoms. A third 
proof involves the timing. Newly generated neurons typically 
require four to five weeks to become fully functioning neurons. 
This is a “latency similar to the onset of therapeutic benefit 
for most…antidepressant medication[s].” This information also 
supports the idea that proper neurogenesis is integral to re-
ducing depressive symptoms. Research has even shown that in 
certain cases, aerobic exercise can foster the same therapeutic 
effects as cognitive therapy (Ernst, et al. 2006).
Further research implicates BDNF (Brain-Derived 
Neurotrophin Factor) in exercise-induced neurogenesis. BDNF 
promotes “neuronal survival and regeneration” in the adult 
brain. Aerobic exercise causes elevated levels of BDNF to be 
produced specifically in the CNS. This specificity indicated that 
BDNF plays a particularly central role, namely in the brain. One 
study found that exercise in mice led to increases in BDNF. They 
also noted that in a case with depressed lab animals, exercise led 
to an increase in both BDNF levels and hippocampal neurogen-
esis. On the other hand, it is known that it is neurogenesis that 
causes the anti-depressant effects of exercise; therefore, it was 
concluded that elevated levels of BDNF contribute to increased 
neurogenesis, thus playing an indirect role in lowering the de-
pressive symptoms. BDNF stimulates cell proliferation specif-
ically in the subgranular zone of the dentate gyrus, and also 
supports long-term survival of these new neurons. A positive 
cycle can thus be recognized: exercise increases BDNF, BDNF 
enhances neurogenesis and neuronal survival, causing increased 
positive affect, probably leading to further exercise to prolong 
the effect (Ernst, et al. 2006).
The obvious question is: why does exercise stimulate neuro-
genesis; what endogenous substance causes the brain to up the 
ante on neurogenesis when the body is engaged in aerobic ac-
tivity? This returns us to the endorphin hypothesis. The thought 
was that endorphins are what stimulate increased neurogenesis, 
in turn causing a decrease in MDD. Studies have found that not 
only do infusions of opiate peptides seem to cause an increase 
in neurogenesis in the dentate gyrus, but also that “opiate re-
ceptor antagonists” seem to cause a decrease in adult neuro-
genesis. Therefore, endorphins may have a role in the survival 
and/or formation of new neurons and glia (Ernst, et al. 2006).
The Endorphin Hypothesis seemed sound, and was sustained 
for decades in the medical arena and among lay athletes at 
large. However, significant holes in the hypothesis were sprung 
that threatened the authenticity of its claims. Among other 
problems, the most substantial issue was that of the Blood 
Brain Barrier (BBB). Blood Brain Barrier describes the pre-
cise “microvasculature of the central nervous system.” It is a 
semipermeable border separating the blood circulation from 
the brain and ECF (extracellular fluid of the CNS). This sys-
tem of tightly packed endothelial cells (in the capillary wall), 
astrocytes (covering the capillaries) and pericytes (embedded 
in the basement membrane of the capillaries) is able to control 
the movement of substances to and from the brain and blood 
circulation. Substances such as “molecules, ions, and cells” are 
screened heavily by the BBB to ensure that no harmful mi-
crobes or other destructive substances reach the brain. This 
system ensures proper neuronal function and protection of the 
brain and spinal cord against “toxins, pathogens, inflammation, 
injury, and disease” (Daneman, R, et al. 2015). Since the cells of 
the BBB are so tightly packed, certain molecules that are too 
large are unable to pass through to gain access to the Central 
Nervous System. An example of such large molecules are beta 
endorphins. They are too bulky to pass through the BBB and 
therefore cannot be the cause any changes to occur within the 
brain. So, while endorphins are indeed released during exer-
cise and may staunch peripheral muscle pain that results from 
exercise, they cannot be the source of any Runners’ High or 
diminished depressive affect (Reynolds, 2015, Fuss, et al. 2015, 
Dietrich, 2004). Other “methodological confounds” inherent in 
the endorphin hypothesis are as follows:
1. Firstly, the possibility of cross reactivity is very strong. Cross 
reactivity occurs when two antigens are very similar in 
their amino acid makeup and therefore an antibody raised 
against one antigen might also bear an affinity for the simi-
lar antigen. The antibody is “programmed” to find the first 
antigen but it also recognizes the second. Beta endorphins 
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bear almost identical amino acid sequences with adreno-
corticotropic hormone (ACTH) and other pro-opiomela-
nocortins. Therefore, any detecting antibody would possibly 
cross-react, making it difficult to detect which is which. 
(Proteintech, 2018) This is a serious confound for scien-
tific experiments involving the authentication of the beta 
endorphin hypothesis and possibly invalidates much of the 
proof presented from these experiments. The fact that en-
dorphins have similar structure specifically to ACTH is a 
further confound, since ACTH is also known to increase 
with endurance exercise.
2. Furthermore, when beta endorphins bind to a µ opioid recep-
tor, it activates the “endogenous opioid system” that further 
activates the “analgesic and euphoric properties” inherent in 
the opiate system. It is also known, however, that symptoms 
such as “severe respiratory depression, pinpoint pupils, and 
inhibition of gastrointestinal motility” are all characteristic of 
endogenous opioid activation (Dietrich, 2004). If it were beta 
endorphins that were activating the opioid system, these 
symptoms would also be present in runners and endurance 
athletes. Since they are not, we are forced to reevaluate what 
it is that truly causes Runners’ High. 
Endocannabinoids
Researchers and scientists have now turned their attention 
to endogenous endocannabinoids as the true source of an-
algesia, sedation, anxiolysis and reduced depression found in 
endurance exercisers (Dietrich, 2004, Heijnen, et al. 2016). 
More recent studies are focusing on endocannabinoids and 
what is it about them that makes exercise “mildly intoxicat-
ing” (Reynolds, 2015). Endogenous endocannabinoids are the 
body’s natural chemicals that improve mood and reduce noci-
ception. They are endogenous lipids that “engage cannabinoid 
receptors, producing analgesic and euphoric effects just like 
those of exogenous cannabinoids, namely marijuana (or can-
nabis - Δ-9-THC ((–)-trans-Δ9-tetrahydrocannabinol; THC) (Lu, 
et al. 2016, Reynolds, 2015). While we now know that opiate 
endorphins mediate analgesia on a peripheral level, we have 
seen that there are still analgesic effects that occur irrespective 
of a working opioid system. This supports the evidence that 
cannabinoid induced analgesia also takes place at a central level 
(Dietrich, 2004). Endocannabinoids are what tell the hypothal-
amus to induce the release of endorphins. Therefore, any an-
algesic effects that endorphins do have are actually mediated 
by endocannabinoids (Heijnen, et al. 2016). Unlike endorphins, 
endocannabinoids are small enough to cross the Blood Brain 
Barrier and bind to brain receptors, thus enabling them to in-
duce peripheral as well as central effects (Fuss, et al. 2015). An 
interesting feature of cannabinoid function is that way they are 
produced. Classic neurotransmitters are created ahead of time 
and stored in their respective synaptic vesicles for whenever 
they might be needed. Cannabinoids, on the other hand, are cre-
ated and released almost immediately on demand. When called 
upon, for example, by G protein coupled receptors or during 
depolarization, endocannabinoids will be “liberated in one or 
two rapid enzymatic steps and released into the extracellular 
space” to produce a rapid effect on the system (Lu, et al. 2016). 
There are two types of identified endocannabinoids, CB1 and 
CB2. CB1 can be found in the CNS, “densely concentrated” in 
the cerebral cortex, hippocampus, basal ganglia; amygdala, hypo-
thalamus and cerebellum (Dietrich, 2004). Most CB1 receptors 
are found on axon terminals and pre-terminal axon segments, 
not on the active zones (Lu, et al. 2016). This further elevat-
ed endocannabinoids over endorphins, for while endorphins 
cannot even cross over in to the brain, endocannabinoids are 
located in the places one would assume pain relievers and an-
algesics would be found. The hippocampus is a site for memory, 
as well as neurogenesis which reduces depression; the amygdala 
regulates the fear response; the hypothalamus is the “master 
gland” of the brain and orchestrates all incoming and outgoing 
activity. The cerebral cortex is a massive conglomeration with 
numerous functions that would be affected by endocannabi-
noids. The frontal lobe of the cortex cares for “higher executive 
functions” such as “emotional regulation, planning [and] reason-
ing…” The parietal lobe is responsible for sensory integration 
such as touch, temperature and pain perception. Thus, is makes 
sense that these areas would abound with CB1 receptors. CB2 
receptors are mainly located in the PNS, expressing themselves 
on immune cells, microglia and vascular elements to protect the 
CNS. (Lu, et al. 2016) There are also cb1 receptors on periph-
eral nerve terminals. For example, “pain sensing [small diame-
ter] C fibers, large diameter Aß and Aδ fibers… [and] dorsal 
root ganglia” (Dietrich, 2004). Therefore, we see that ECBs are 
synthesized both centrally and peripherally, unlike endorphins 
which hare only synthesized in the Peripheral Nervous System. 
The possibility of a third cB receptor is currently being inves-
tigated and may turn out to account for some of the Runners’ 
High effects.
Chief ligands of CB1 and CB2 receptors are anandamide 
(arachidonoyl ethanolamine) and 2-arachidonoyl glycerol (2-
AG) (Lu, et al. 2016). They are derived from fatty acid deriva-
tives. Anandamide is known to bind with cb1 receptors over 
cb2 receptors, indicating higher central activity over peripheral 
activity (Dietrich, 2004). Anandamide (AEA) is a “highly lipophil-
ic” fatty chemical and therefore can easily cross in to the brain 
proper (Heijnen, et al. 2016). This would implicate anandamide in 
activating analgesic effects in the brain (Dietrich, 2004). AEA in-
creased gradually when cortisol is released during the HPA Axis, 
demonstrating a role in regulation of stress and amygdalar over 
excitability (Heijnen, et al. 2016). Rats showed an increase in hip-
pocampal anandamide after running on a wheel for an extended 
period of time, indicating that anandamide plays a role in exercise 
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and homeostatic regulation (Fuss, et al. 2015). Additionally, anan-
damide acts as a vasodilator and produces hypotension, facilitat-
ing blood flow during exercise (Dietrich, 2004). 
Anandamide (AEA) also engenders elevated levels of BDNF 
(Brain Derived Neurotrophic Factor) during exercise and return 
to baseline levels post-exercise. As mentioned above, BDNF is 
part of the neurotrophin family and plays a strong role in ex-
ercise-induced neurogenesis. In addition to promoting positive 
affect due to neurogenesis, BDNF also “exerts beneficial effects 
on cognition through its ability to enhance neurogenesis, synap-
tic plasticity and long-term potentiation, the basis of learning.” 
Therefore, enhanced release of AEA due to exercise stimulates 
BDNF to stimulate heightened cognition and learning. Indeed, 
psychological stress and mood disorders have been found to re-
duce BDNF levels in the brains of rats and mice. Physical stress, 
or aerobic exercise, does just the opposite. A study among an 
elderly population showed that “moderate intensity walking” 
over a year served to intensify BDNF levels, further causing task 
switching functioning to remain constant. The control group of 
sedentary elderly showed a diametric decline in BDNF and 
in task switching as well (Heijnen, et al. 2016). Other studies 
have shown that aerobic activity “ranging from 20 to 90 min 
of 40–75% of maximal power output or 40–60% of VO2max 
or 75% of maximal heart rate” causes noticeable increases in 
BDNF levels (Heijnen, et al. 2016). Thus endocannabinoids play 
a role in cognition and mood as well.
Scientists noted that there were elevated levels of both en-
dorphins and endocannabinoids in the plasma of mice, post run 
(Reynolds, 2015). In one experiment, the cB receptors in mice 
were blocked, noticeably inhibiting the Runners’ High that is 
usually induced post run. The mice were anxious and sensitive 
to pain perception. Blocking the endorphin receptors had no 
effect and the mice experienced the calming and antinociceptive 
effects of runners’ high as usual (Fuss et al., 2015, Reynolds, 
2015). A similar study also involved lab mice running in a wheel. 
First off, increased running directly increased levels of endocan-
nabinoids, effectively inducing a reduction in anxiety and pain. 
Furthermore, ablation of the mice’s cb1 receptors completely 
inhibited the runners’ high effect, eliminating anxiolysis. When 
the mice were injected with blockers of their cB receptors, 
the analgesic effects were further inhibited (Fuss, et al. 2015). 
Yet another study with mice divided the mice into running and 
non-running groups. The running mice were at ease to spend 
more time in bright light areas, something anxious mice don’t 
do. This indicated that the running induced sedation. The mice 
were also tested for pain perception with a hot plate test. The 
runners did not jump in pain or lick their paws as much as 
normal, indicating that running induced antinociception, endow-
ing the mice with heightened “thermal pain sensitivity.” All of 
these studies found that reductions in anxiety and elevated se-
dation in mice are due to increased CB1 receptors in forebrain 
GABAergic neurons, while antinociception was caused by cb1 
and cb2 receptors in the PNS (Fuss, et al. 2015). This antinoci-
ceptive effect can even rival that of morphine (Dietrich, 2004). 
Another study engaged healthy male athletes running at 
“varying degrees of intensity” over a period of four days. Each 
running session induced a 70-80% raise in basal heart rate, and 
was performed at 50-90% of maximal intensity capacity. A sharp 
increase in cB1 receptors was found in the “frontal cortex, 
amygdala, hippocampus, and…hypothalamus” all known to be 
essential areas that regulate affective homeostasis (Heijnen, et 
al. 2016). A similar study involved male college athletes exercis-
ing on treadmills or stationary bikes at 70-80% maximal heart 
rate. After about an hour, drastically raised levels of anandamide 
were measured in their blood circulation (Dietrich, 2004). 
Another way that endocannabinoids modulate nociception 
is by affecting the Periaqueductal Gray system (PAG). The PAG 
serves an important role in modulating ascending pain transmis-
sion, fielding “afferents from nociceptive neurons in the spinal 
cord [and sending] projections to thalamic nuclei that process 
nociception.” In regard to descending pain inhibition, the PAG 
inhibits neurons in the dorsal horn of the spinal cord. The major 
functions of the midbrain periaqueductal gray (PAG) include 
suppressing pain, fear and anxiety, and promoting analgesia and 
cardiovascular control” (Bebehani, 1995). “Electrical stimulation 
of [both] the dorsal and lateral periaqueductal gray system” 
causes not only bindings to cb1 receptors but a subsequent re-
lease of anandamide into circulation. Additionally, an experiment 
revealed that “subcutaneous injection of the chemical irritant 
formalin” caused a direct infusion of the ligand anandamide into 
the periaqueductal gray. This implicates anandamide as a noci-
ceptive agent for central chemogenic pain (Dietrich, 2004). 
Upon observation, it can be noted that runners’ high is only 
found in response to endurance exercise, as opposed to exer-
cise in spurts. Sports such as “sprinting…weightlifting…track, 
soccer, football, tennis [and] basketball” doubtfully engage the 
endocannabinoid system since they do not involve long term 
exertion (Dietrich, 2004). Running, dancing or biking are ex-
amples of activities that would engage the ECB system and 
induce a runners’ high. As mentioned earlier, endorphins play 
a role in moderating only peripheral chemogenic pain in the 
muscles. In addition to the central effects of anandamide, we 
find that cannabinoids also act similarly to inhibit edema and 
muscle inflammation that might occur during intense exercise. 
This moderation is important for endurance athletes because 
muscle pain is a cause and effect of lactic acidosis, which in turn 
introduces symptoms like muscle ache, nausea and stomach 
pain (Dietrich, 2004). 
Endogenous cannabinoids and exogenous cannabinoids (mar-
ijuana) act in similar fashions. “The psychoactive constituent of 
marijuana, Δ-(9)-tetrahydrocannabinol (THC), exhibits high af-
finity for the CB1 receptor, which is densely expressed in brain 
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regions implicated in the control of emotion and cognition.” 
Therefore, just like marijuana, ECBs can induce sedation, analge-
sia, reduced anxiety, euphoria and even impaired spatial learning 
(Dietrich, 2004). This essentially means that prolonged exercise 
produces the same effects as marijuana. 
This leads into the addictive quality of endurance exercise. 
The endocannabinoid system is closely linked with the dopa-
minergic reward system of the brain. Dopamine is the brain’s 
pleasure hormone, and dopamine receptors D1 and D2 are 
modulated by endocannabinoids. The two main ECB ligands 
anandamide and 2-arachidonoylglycerol (2-AG) proliferate in 
dopaminergic pathways as a “retrograde feedback system” for 
GABA nerve terminals. There, they modulate dopamine trans-
mission (Bloomfield, et al. 2016). Additionally, cBs affect dopa-
mine activity by increasing firing rates in the medial forebrain 
bundle, ventral tegmentum and substantia nigra. In the same 
vein, withdrawing the cB presence would induce withdrawal 
symptoms similar to that characteristic of marijuana withdrawal. 
This is due to reduced firing of the pleasure hormone dopa-
mine. Therefore, endogenous as well as exogenous cannabinoids 
(CB1) are what cause the influx of dopamine release into cir-
culation, thus causing a feel-good high or a “Runners’ High.” Just 
like exogenous ECB cause drug addiction, so too endogenous 
ECBs engender an addiction to that which brings on the dopa-
minergic feelings, namely aerobic exercise. This explains exercise 
addiction; exercise causes elevated levels of ECBs, ECBs in turn 
cause increased firing of dopamine, inducing an addictive “high.” 
Indeed, it has been found that even just blocking dopamine 
receptors inhibits Runners’ High. Athletes who are forced to 
refrain from their routine endurance exercise (for example, in 
the case of an injury) report withdrawal symptoms not unlike 
those of drug withdrawal (Dietrich, 2004). 
Conclusion 
The analgesic, euphoric and anti-depressant effects that take 
hold in response to aerobic exercise have been a major source 
of contention among the medical, scientific and lay community 
for decades. The endorphin hypothesis certainly took center 
stage for quite a time as the source behind what the vernacular 
aptly termed “Runners’ High.” However, compelling evidence, 
experimental proofs and biological veracities have enabled sci-
entists to ascertain that endogenous endocannabinoids are the 
underlying cause of the many positive effects of aerobic activity. 
Included in these positive effects are: elevated ACTH to regulate 
the stress response, heightened BDNF production to promote 
neurogenesis and neural survival, analgesia, anxiolysis, decreased 
anxiety and depression, euphoria, enhanced cognition, and nu-
merous others. Endorphins do not cause Runners’ High; how-
ever, they do engender other positive effects during exercise. 
Exercise has been seen to induce Runners’ High in all ages and 
stages, be it depressed or emotionally healthy, young or elderly, 
and male or female. With this knowledge, the proof holds true 
that enhanced release of endogenous endocannabinoids due 
to aerobic activity reliably and consistently induces a Runners’ 
High, and thus decreases the depressive symptoms inherent in 
Major Depressive Disorder. 
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